Wilmot Cancer Institute has a longstanding strength in the study of blood cancers—and from Dec. 9-12, many of our scientists will be presenting research at the 59th annual meeting of the American Society of Hematology (ASH) in Atlanta. With more than 17,000 members, ASH is the largest professional society for physicians and scientists who are working to conquer blood diseases.
Award Highlight: On Sunday, Dec. 10, ASH will honor Marshall A. Lichtman, M.D., with the Wallace H Coulter Award for Lifetime Achievement, for more than 50 years of outstanding service to the field. Lichtman, 83, is a University of Rochester hematologist/oncologist, textbook author, educator, mentor, and former dean of the UR School of Medicine and Dentistry. Learn more about Lichtman’s ASH award.
Lichtman will be in good company at the ASH honorees ceremony: In addition to other notable physicians and scientists, former Vice President Joe Biden will receive the ASH Public Service Award for leading the Cancer Moonshot initiative to accelerate cancer research, and former NBC Nightly News anchor Tom Brokaw will be honored for his dedication to increasing public awareness about cancer since his diagnosis of multiple myeloma.
Wilmot Research Highlights: Many faculty from the Wilmot Cancer Institute are presenting data and conducting workshops at ASH on leukemia, lymphoma, myelodysplastic syndromes (MDS), anemia, and the process that blood cells undergo during disease transformation.
Oral presentations include:
- The aging of blood stem cells. Corey Hoffman, Ph.D., who recently earned his doctorate while conducting research in the Laura Calvi lab, will discuss their discovery that a novel sequence of events as blood cells age leads to leukemia and other blood diseases; and they have identified an existing drug that could help to eliminate the inflammation in the blood system that contributes to the disease process.
- Identification of risk factors for progression and early death from follicular lymphoma. Carla Casulo, M.D., will present the findings of a pooled analysis of more than 5,000 patient cases, outlining the well-defined risk factors that could be used to place those patients in clinical trials.